Zura Bio (NASDAQ:ZURA - Get Free Report) is anticipated to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Zura Bio to post earnings of ($0.17) per share for the quarter.
Zura Bio Stock Down 0.7 %
Zura Bio stock traded down $0.01 during midday trading on Friday, reaching $1.39. The stock had a trading volume of 309,952 shares, compared to its average volume of 396,825. The firm's fifty day simple moving average is $1.51 and its 200-day simple moving average is $2.81. Zura Bio has a 1-year low of $1.07 and a 1-year high of $6.35.
Analysts Set New Price Targets
ZURA has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Zura Bio in a research report on Wednesday, December 11th. HC Wainwright reaffirmed a "neutral" rating and set a $5.00 price target on shares of Zura Bio in a research report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Zura Bio has an average rating of "Buy" and a consensus price target of $15.80.
Get Our Latest Stock Report on ZURA
Institutional Inflows and Outflows
An institutional investor recently raised its position in Zura Bio stock. Bank of America Corp DE increased its holdings in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) by 31.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 41,222 shares of the company's stock after acquiring an additional 9,966 shares during the quarter. Bank of America Corp DE owned about 0.06% of Zura Bio worth $103,000 as of its most recent SEC filing. 61.14% of the stock is currently owned by institutional investors and hedge funds.
Zura Bio Company Profile
(
Get Free Report)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.
Further Reading
Before you consider Zura Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zura Bio wasn't on the list.
While Zura Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
